VOICED : Falla un medicamento de Novartis contra el covid-19

Novartis announced that their clinical trials for Ruxolitinib, aimed at treating severe COVID-19 cases, did not yield the expected results in reducing hospitalizations. The Phase 3 trial showed no significant improvement, but this does not affect ongoing research for other diseases. Ruxolitinib is already marketed under the name Havaki for other uses. Novartis plans to continue working with the medical community to analyze these results and gain a better understanding of COVID-19. For more details, visit www.alimmenta.com.

What was the outcome of the clinical trials for Ruxolitinib in severe COVID-19 cases?

• It showed significant improvement.

• It showed no improvement.

• It worsened the condition.

• It was inconclusive.

What was the expected result of the phase 3 study for Ruxolitinib?

• Increase in hospitalizations.

• No change in patient condition.

• Reduction in hospitalizations.

• Complete recovery of patients.

What is Ruxolitinib marketed as for other conditions?

• Ruxcovid

• Havaki

• Alimmenta

• Novartis

What will Novartis focus on after the trial results?

• Discontinuing Ruxolitinib.

• Stopping all research on COVID-19.

• Analyzing results with the medical community.

• Developing a new drug.

Where can more information about the study be found?

• www.ruxolitinib.com

• www.alimmenta.com

• www.covid19.com

• www.novartis.com